Zhuang Yu

Qingdao University - Affiliated Hospital

China

SCHOLARLY PAPERS

4

DOWNLOADS

139

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Number of pages: 37 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Central South University - Thoracic Medicine Department II, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Jilin Cancer Hospital, China Medical University - Medical Oncology Department of Thoracic Cancer, Guangdong Pharmaceutical University - Department of Medical Oncology, Xuzhou Central Hospital, Jiangnan University - Affiliated Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Harbin Medical University, Wenzhou Medical University - Taizhou Hospital of Zhejiang Province, Linyi Cancer Hospital - Department of Medical Oncology, Zhejiang University - Second Affiliated Hospital, The First Affiliated Hospital of Guangxi Medical University, Shanghai Jiao Tong University (SJTU) - Department of Respiratory and Critical Care Medicine, Tangshan People’s Hospital, Shandong University - Shandong Cancer Hospital, Qingdao Central Hospital, ZhongDa Hospital of Southeast University, Huazhong University of Science and Technology - Department of Medical Oncology, Nanchang University - First Affiliated Hospital, Zhengzhou University - Henan Cancer Hospital, Government of the People's Republic of China - Second People's Hospital of Yibin, Peking University - Department of Thoracic Medical Oncology, Medical School of Nanjing University, Xiamen University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Zhengzhou University - Department of Oncology, Xinjiang Medical University - Affiliated Tumor Hospital, China Medical University - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Nanchang University - Department of Medical Oncology, Shandong University - Qilu Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University - Department of Medical Oncology, Nanjing University - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Guangzhou Medical University - Second Affiliated Hospital, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Nantong Tumor Hospital - Department of Medical Oncology, First People's Hospital of Changzhou, Chongqing Medical University - Second Affiliated Hospital, Jilin University (JLU) - Cancer Center, Shanghai Jiao Tong University (SJTU) - Ruijin Hospital of Shanghai, Yangzhou University - Subei People's Hospital of Jiangsu Province, Anhui Provincial Cancer Hospital, Shanxi Provincial People's Hospital, Shanxi Provincial People's Hospital, Chinese Academy of Medical Sciences - Cancer Hospital, Nanjing Medical University - Nanjing First Hospital, Nanjing Medical University - Department of Oncology, ChangZhou Cancer Hospital, Nantong University - Department of Respiratory Medicine, First Hospital of Jiaxing, Fujian Provincial Cancer Hospital, Ground Force Medical University - Xinqiao Hospital, Xi’an Jiaotong University, Health Science Center, First Affiliated Hospital, TopAlliance Biosciences, TopAlliance Biosciences, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Shanghai Junshi Biosciences Co., LTD, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 45 (824,020)

Abstract:

Loading...

Non-small cell lung cancer, overall survival, immunotherapy, biomarker

2.

Epidemiology, Prevention, and Treatment of Chemotherapy-Induced Myelosuppression in China: A National Cross-Sectional Study

Number of pages: 29 Posted: 04 Jan 2024
Nanjing Medical University - Jiangsu Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Southern Medical University - Department of Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Xuzhou Medical University - Affiliated Hospital, Qingdao University - Affiliated Hospital, Hebei Medical University - Fourth Hospital, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Central South University - Thoracic Medicine Department II, Xi'an Jiaotong University (XJTU), Second Affiliated Hospital, Peking University - Peking University Cancer Hospital & Institute, Peking University International Hospital, Jilin Cancer Hospital, Zhengzhou University, Shanghai Jiao Tong University (SJTU) - Department of Oncology, Anhui Medical University, Huazhong University of Science and Technology - Cancer Center, Tianjin Medical University - Tianjin Medical University Cancer Institute and Hospital, Shanxi Bethune Hospital, Harbin Medical University, Cancer Hospital, Department of Internal Medicine, Harbin Medical University, Cancer Hospital, Department of Internal Medicine, Fujian Medical University - Department of Thoracic Oncology, Guangxi Medical University - First Affiliated Hospital, University of Electronic Science and Technology of China (UESTC) - Sichuan Provincial People’s Hospital, Jiangxi Cancer Hospital, Hainan Cancer Hospital, Xinjiang Medical University - Affiliated Cancer Hospital, Kunming Medical University - Third Affifiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Sun Yat-sen University (SYSU), Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China and Nanjing Medical University - Jiangsu Cancer Hospital
Downloads 40 (871,349)

Abstract:

Loading...

Chemotherapy, Myelosuppression, Epidemiology, Prevention, Treatment, Cross-Sectional

3.

Prophylactic Cranial Irradiation Improved the Prognosis in pT1-2N0M0 Small Cell Lung Cancers after Complete Resection

Number of pages: 33 Posted: 09 Aug 2024
Qingdao University, Qingdao University, Qingdao University, Qingdao University, Qingdao University, Qingdao University, Qingdao University, Qingdao University - Affiliated Hospital, Qingdao University and Qingdao University - Department of Radiation Oncology
Downloads 30 (953,621)

Abstract:

Loading...

prophylactic cranial irradiation, brain metastasis, small cell lung cancer, adjuvant therapy, survival advantage

4.

Rezivertinib Versus Gefitinib as First-Line Therapy for EGFR-Mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-Blinded, Randomized Phase 3 Study

Number of pages: 26 Posted: 13 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Henan University of Science and Technology - Department of Medical Oncology, Zhengzhou University - Department of Oncology, Central South University - Thoracic Medicine Department II, People's Hospital of Deyang City, Shanxi Medical University - First Hospital, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Respiratory Medicine, Sichuan Cancer Hospital - Department of Medical Oncology, Chongqing University Cancer Hospital - Department of Palliative Care, Sichuan University - Department of Respiratory and Critical Care Medicine, Guangxi Medical University, Shandong First Medical University - Department of Oncology, Qingdao University - Yantai Yuhuangding Hospital, Fujian Medical University - Fujian Cancer Hospital, Shantou University - Department of Medical Oncology, Linyi Cancer Hospital - Department of Medical Oncology, Army Medical University - Institute of Cancer, Xingtai Medical College - Cancer Center, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Gannan Medical University - First Affiliated Hospital, Central South University - Department of Respiratory Medicine, University of South China, Central South University, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Xinjiang Medical University - Pulmonary Cancer Medicine, Hubei University of Arts and Science - Department of Oncology, Xinjiang Medical University, Zhengzhou University - Henan Provincial People's Hospital, Qingdao University - Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Jilin University (JLU) - Cancer Center, Peking University - Department of Thoracic Medical Oncology, Cangzhou Central Hospital, Xi'an Jiaotong University (XJTU), China Medical University - Liaoning Cancer Hospital & Institute, Xiangtan Central Hospital, Nankai University - Tianjin Chest Hospital, Nanjing Medical University - Department of Oncology, Xiamen University, Huazhong University of Science and Technology - Department of Medical Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Henan University - Department of Oncology, Ningbo No. 2 Hospital, Zhengzhou University - Department of Medical Oncology, Shijiazhuang People’s Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Chifeng Municipal Hospital, Handan Central Hospital - Department of Oncology, Tianjin Medical University - The Second Hospital of Tianjin Medical University, Government of the People's Republic of China - Army Medical University, Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 24 (1,016,812)

Abstract:

Loading...

rezivertinib, gefitinib, NSCLC, EGFR TKI.